We are pleased to announce our participation in i2.JP, an initiative launched by AstraZeneca to connect parties such as start-ups, healthcare professionals, local governments, academia and private companies. i2.JP aims to joinly solve problems in the healthcare sector and to come up with practical and optimal solutions.
We as HIROTSU Bio Science Inc. (Head Office: Chiyoda-ku, Tokyo; Representative: Takaaki Hirotsu (Hereinafter referred to as “HIROTSU”) are pleas . . .
2024.04.01On March 18, 2024, an reveiw articles on cancer screening by a third-party research team (Romania) was published in "Cancers", an oncology journ . . .
2024.03.29HIROTSU Bioscience Inc. (Head Office: Chiyoda-ku, Tokyo, Representative: Takaaki Hirotsu, hereinafter referred to as “HIROTSU) has verified the . . .
2024.02.29